European Pharmaceutical Review

JULY 1, 2024

the CHMP gave a positive opinion for the first nasally administered emergency treatment for allergic reactions” A positive opinion was granted to the mResvia (Respiratory Syncytial Virus (RSV) mRNA vaccine). EMA’s human medicines committee decided to revoke the conditional marketing authorisation for Ocaliva. 1 virus variant.

Generic Medicine 106

Generic Medicine Vaccines 106

European Pharmaceutical Review

FEBRUARY 26, 2024

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. These products were designated as an orphan medicine during their development.

Generic Medicine 98

Generic Medicine Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

European Pharmaceutical Review

APRIL 25, 2024

percent between 2024 and 2031. Main drivers for the market were reported to be rising popularity of generics together with blockbuster and other small-molecule drugs going off-patent globally. Overall, increasing demand for generic medicines will be a significant factor for growth. billion by 2031.

Packaging 98

Packaging Generic Medicine Vaccines 98

European Pharmaceutical Review

FEBRUARY 3, 2025

CHMP’s positive opinions for vaccines In addition, the human medicines committee recommended the vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine (21-valent)), as a preventative treatment for invasive disease and pneumonia caused by streptococcus pneumoniae bacteria in adults.

Generic Medicine 52

Generic Medicine Vaccines Chemotherapy Immunization 52